Clinical Research

Prevail Therapeutics Inc.

Address
430 East 29th Street Ste 1520

Sponsor Overview

assignment
4
sponsored trials
science
6
molecules
location_city
11
research centres
public
5
countries
person_search
11
investigators

Specializations

Neurodegenerative Disorders

Prevail Therapeutics Inc. funds clinical research in Parkinson’s disease and fronto-temporal dementia, with a particular focus on forms linked to GBA1 and progranulin biology.

  • Parkinson’s disease
  • Parkinson’s disease with GBA1 mutation
  • Fronto-temporal dementia with progranulin mutations

The sponsor’s research in this area centers on neurological conditions associated with inherited molecular subtypes and disease-related protein regulation.

Lysosomal Storage Disorders

The company also supports studies in Type 1 Gaucher disease, specifically the peripheral and non-neuronopathic manifestations of the disorder.

  • Type 1 Gaucher disease
  • Peripheral manifestations
  • Non-neuronopathic disease

This area reflects interest in inherited lysosomal conditions with systemic involvement beyond the central nervous system.

Genetic Disease Mechanisms

Across its trial portfolio, Prevail Therapeutics Inc. concentrates on diseases driven by specific genetic alterations, including progranulin mutations and GBA1 mutations.

  • Progranulin deficiency
  • GBA1-related pathology
  • Inherited neurodegeneration

Its clinical research interests align with disorders where molecular defects are closely tied to neurological and lysosomal dysfunction.

Central Nervous System and Biomarker Research

The sponsor’s trials include evaluation of progranulin levels in blood and cerebrospinal fluid, alongside other measures relevant to central nervous system disease biology.

  • Blood biomarker assessment
  • Cerebrospinal fluid biomarkers
  • Central nervous system involvement

These research interests support clinical investigation in neurological diseases where biomarker changes are linked to underlying pathophysiology.

Sponsored Trials

Trial Name Country Status
A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)Belgium BelgiumFrance FranceNot Recruiting
An Open-label, Dose-Finding, Phase 1/2 Study to Evaluate the Safety and Tolerability of a Single Intravenous Dose of LY3884961 in Subjects with Peripheral Manifestations of Gaucher DiseaseGermany GermanySpain SpainNot Yet Recruiting
Evaluation of Safety and Efficacy of LY3884961 in Parkinson's Disease Patients with GBA1 Mutation: A Phase 1/2a Open-Label Ascending Dose StudyThe Netherlands The NetherlandsNot Yet Recruiting
Evaluation of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of LY3962681 in Healthy Volunteers and Patients with Parkinson's DiseaseGermany GermanyThe Netherlands The NetherlandsNot Yet Recruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
2
Exclusive Molecules
out of 6 total (33% not shared with other sponsors)

This sponsor works with 6 molecules, of which 2 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
0%
Return partnership rate
0 of 11 sites collaborated multiple times

This sponsor has worked with 11 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Nervous System Diseases3 trials
    449 other sponsors
  • 2.
    Congenital, Hereditary, and Neonatal Diseases and Abnormalities1 trial
    165 other sponsors

Partnered Research Centres

11 centres
location_city
assignment966
Assistance Publique Hopitaux De Marseille
Address
264 Rue Saint Pierre, 13005 Marseille
Learn morearrow_forward
location_city
assignment79
Centre for Human Drug Research
Address
Zernikedreef 8, 2333 CL Leiden
Learn morearrow_forward
location_city
assignment1015
Centre Hospitalier Universitaire De Lille
Address
Rue Michel Polonovski, 59037 Lille
Learn morearrow_forward
location_city
assignment1617
Hopital Beaujon
Address
100 Boulevard Du General Leclerc, 92110 Clichy
Learn morearrow_forward
location_city
assignment15
Hospital Quironsalud Zaragoza
Address
Paseo Renovales S/n, 50006 Zaragoza
Learn morearrow_forward
location_city
assignment1165
Katholieke Universiteit te Leuven
Address
Herestraat 49, 3000 Leuven
Learn morearrow_forward
Page 1 of 2

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Prevail Therapeutics Inc..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.